The use of antidepressants in oncology: a review and practical tips for oncologists

Grassi, Luigi; Nanni, Maria Giulia; Rodin, Gary; Li, M.; Caruso, Rosangela

doi:10.1093/annonc/mdx526

Cited by 60 publications

(41 citation statements)

References 114 publications

(122 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Selective serotonin reuptake inhibitors and Selective noradrenergic and serotonin reuptake inhibitors) have been shown to help in treating depression and anxiety and cancer-related symptoms, such as hot flashes and pain 72 , 73 . With respect to this, it is important for clinicians, usually psychiatrists but also oncologists and primary care physicians, to have proper training on the use of the drugs, their side effects, and their interactions with other cancer treatment in oncology 74 , 75 .…”

Section: Evidence-based Psychosocial Interventionmentioning

confidence: 99%

Advancing psychosocial care in cancer patients

2017

View full text Add to dashboard Cite

Cancer is a devastating disease causing significant psychological problems among patients and their families. In the past few decades, there have been growing implementation and dissemination of screening methods for the psychological consequences of cancer, including distress, depression, anxiety, post-traumatic stress, and demoralisation. Also, guidelines for the management of psychological distress have been developed and endorsed by a number of scientific cancer associations. This review examines some of the most significant related issues, also focusing on recent advances in psychosocial and psychopharmacological interventions as a part of a mandatory, integrated, and comprehensive approach to cancer care.

show abstract

Section: Evidence-based Psychosocial Interventionmentioning

confidence: 99%

Advancing psychosocial care in cancer patients

2017

View full text Add to dashboard Cite

show abstract

“…Antidepressants have been used for the treatment of depression in cancer patients, but they have been shown a negative effect on compliance with the anticancer treatment [4,7]. Considering the interaction among antidepressants and anticancer drugs, the use of antidepressants with anticancer effects may reduce their side effects in the treatment of depressed people with cancer.…”

Section: Introductionmentioning

confidence: 99%

Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation

Cho

Kim

Nyiramana

et al. 2019

Cancers

View full text Add to dashboard Cite

Depression is more common in women with breast cancer than the general population. Selective serotonin reuptake inhibitors (SSRIs), a group of antidepressants, are widely used for the treatment of patients with depression and a range of anxiety-related disorders. The association between the use of antidepressant medication and breast cancer is controversial. In this study, we investigated whether and how SSRIs induce the death of human breast cancer MCF-7 cells. Of the antidepressants tested in this study (amitriptyline, bupropion, fluoxetine, paroxetine, and tianeptine), paroxetine most reduced the viability of MCF-7 cells in a time-and dose-dependent manner. The exposure of MCF-7 cells to paroxetine resulted in mitochondrion-mediated apoptosis, which is assessed by increase in the number of cells with sub-G1 DNA content, caspase-8/9 activation, poly (ADP-ribose) polymerase cleavage, and Bax/Bcl-2 ratio and a reduction in the mitochondrial membrane potential. Paroxetine increased a generation of reactive oxygen species (ROS), intracellular Ca2+ levels, and p38 MAPK activation. The paroxetine-induced apoptotic events were reduced by ROS scavengers and p38 MAPK inhibitor, and the paroxetine’s effect was dependent on extracellular Ca2+ level. Paroxetine also showed a synergistic effect on cell death induced by chemotherapeutic drugs in MCF-7 and MDA-MB-231 cells. Our results showed that paroxetine induced apoptosis of human breast cancer MCF-7 cells through extracellular Ca2+-and p38 MAPK-dependent ROS generation. These results suggest that paroxetine may serve as an anticancer adjuvant to current cancer therapies for breast cancer patients with or without depression.

show abstract

“…The significant advances in research in the area of psycho-oncology have favoured the development, implementation and dissemination of psychosocial guidelines and evidence-based treatments for several co-morbid psychiatric disorders in cancer, such as depression (Li et al ., 2017) and anxiety (Traeger et al ., 2012). Screening, identification and access to evidence-based psychosocial approaches for cancer patients in distress must be provided, both in the hospital and in community settings (Lazenby, 2015; Andersen and Dorfman, 2016; Grassi et al, 2018). Besides specific cancer care specialists, primary care should also take responsibility in its role of provision of continuous, coordinated and comprehensive care for individuals with cancer and families.…”

Section: Discussionmentioning

confidence: 99%

Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions

Caruso

Breitbart

2020

Epidemiol Psychiatr Sci

Self Cite

View full text Add to dashboard Cite

With cancer incidence increasing over time worldwide, attention to the burden of psychiatric and psychosocial consequences of the disease is now mandatory for both cancer and mental health care professionals. Psychiatric disorders have been shown to affect at least 30–35% of cancer patients during all phases of the disease trajectory, and differ in nature according to stage and type of cancer. Other clinically relevant distressing psychosocial and existential conditions (e.g. demoralisation, health anxiety, loss of meaning and existential distress) not included as ‘disorders’ in the usual diagnostic and nosological systems (i.e. meta-diagnostic conditions) have also been shown to be present in another 15–20% of cancer patients. In this editorial, we will present a summary of the extensive literature regarding the epidemiology of the several psychosocial disorders affecting cancer patients as a cause of distress and burden to be taken into consideration and addressed in cancer care through evidence-based intervention.

show abstract

The use of antidepressants in oncology: a review and practical tips for oncologists

Cited by 60 publications

References 114 publications

Advancing psychosocial care in cancer patients

Advancing psychosocial care in cancer patients

Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation

Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions

Contact Info

Product

Resources

About